- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test<figure><div><img src="https://imgproxy.divecdn.com/-VJqYiEfcoBd7qksclMxxfyJncEOUGAsA4I3KzG8Vpc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzM4Mzc0MDE5LmpwZ…BioPharma Dive · 1mo ago↗ source
- Exclusive: Genentech closes infectious disease unit in wave of research layoffsRoche's Genentech underwent another round of layoffs this week in its early research and development group, Endpoints News has learned, which included shuttering two research units and the departur…Endpoints · 1mo ago↗ source
- Rare disease biotech Beren adds $300M from new financingsAnxiously awaiting an FDA decision this fall, Beren Therapeutics has added $300 million in new capital to help launch its rare disease drug. The biotech announced Wednesday that it raised $135 ...